Several fatalities have resulted. It is now recommended that for a given attack, if a patient does not respond to the first dose, the diagnosis of migraine headache should be reconsidered before administration of a second dose. Following a satisfactory cardiovascular assessment, it is strongly recommended that these patients receive their first dose of sumatriptan in the physician's office. The revised package insert also incorporates information about a new drug interaction. August and November 1994.
Intravenous colchicine is used for the management of acute gouty arthritis attacks.
Resuscitative treatments and equipment should be readily available. The pediatric strength will be stocked as soon as it is commercially available. The 500 mg strength is still available. The 50 mg strength is still available. The 1 mg vial is still available.